To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

May 29, 2020

“Having A Say” with Dellann

Photo of Dellann along with an office scene

Would you like a full hour with our President & CEO, Dellann Elliott Mydland?

We want to know your thoughts, your feelings, your frustrations, your challenges, your joy, your HOPE and more! Dellann has spent over 18 years advocating for patients and their caregivers in the Brain Tumor Community. She is passionate about getting people the care they NEED at the time they NEED it.

Over the years she has been able to refer hundreds of patients to specialists, next generation sequencing opportunities, tumor tissue saving protocols, immediate clinical trial enrollment and much more.

Another part of Dellann’s work includes advocating & testifying for multiple FDA treatment options for patients that have since been approved. She has also successfully advocated for policy changes relating to clinical practice, Medicare/Medicaid, health insurance coverage, and corporate reimbursements for brain cancer treatment options.

*If you would like to read Dellann’s personal message to the Brain Tumor Community about this new “Have A Say” with Dellann program, please click HERE.

Dellann’s mission is to capture the “Patient Voice” and she wants to hear from YOU! Each week on Thursday’s at 11am PST, she will be hosting a FREE (limited) chat session with anyone involved in the brain cancer community whether it be patients, caregivers, family members, industry, business development professionals, and corporate sponsors. You must preregister for these sessions as we are limiting the amount of people involved each week in the interest of making sure that everyone feels heard! NOW is the time to register. If we receive your registration after your desired session date is full, you will be contacted with alternative dates so please be patient!


Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
corporate partners
upcoming events
About us
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram